Peptomyc

peptomyc.com ↗ ·Barcelona ·Series A

Peptomyc is a Barcelona-based clinical-stage biotech developing first-in-class cell-penetrating mini-protein therapeutics that directly inhibit the MYC oncoprotein, a driver implicated in the majority of human cancers. Spun out of the Vall d'Hebron Institute of Oncology (VHIO) and ICREA in December 2014 by Laura Soucek and Marie-Eve Beaulieu, its lead asset OMO-103 (Omomyc) became the first MYC inhibitor to demonstrate safety and anti-tumor activity in a human clinical trial. The company has raised roughly €28-31M in equity across Seed, Series A, B and C rounds plus ~€11M in public funding, and is led today by CEO Jesus Martin Garcia with co-founder Laura Soucek as Chief Scientific Officer.

Founded

2014

Founders

Total funds raised

€28M

SectorsBiotech, Oncology, Drug Discovery, Therapeutics, Life Sciences Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Laura Soucek

Co-Founder and Chief Scientific Officer (CEO until 2025)

Marie-Eve Beaulieu

Co-Founder (former Chief Scientific Officer)

Global models 5

Parabilis Medicines

United States · www.parabilismed.com ↗

Makes cell-penetrating Helicon peptide drugs that hit intracellular cancer targets once seen as undruggable, the same approach as Peptomyc's cell-penetrating mini-proteins.

$1.1BComparable

Dewpoint Therapeutics

United States · www.dewpointx.com ↗

Clinical and preclinical oncology biotech going after hard-to-drug transcription drivers, including MYC, through a VC-funded pipeline built for pharma deals.

$300MComparable

Circle Pharma

United States · www.circlepharma.com ↗

Develops cell-permeable macrocyclic peptides that block intracellular cancer drivers, now in clinical trials, a similar peptide-against-undruggable-oncology model.

$250MComparable

Kronos Bio

United States · www.kronosbio.com ↗

Was VC-backed to drug MYC-driven transcriptional programmes in cancer, the same first-in-class MYC thesis as Peptomyc.

$155MComparable

Aileron Therapeutics

United States · www.aileronrx.com ↗

Developed cell-penetrating stapled peptides against intracellular protein-protein interactions (MDM2/MDMX) and took them into clinical oncology trials.

$100MComparable

In the same niche 67 others

See all in the Start-ups Map →

Highlight Therapeutics

+61 more →

Notes: Most funded first

Investors 9

Open as list →

Alta Life Sciences

www.altalifesciences.com

4 rounds, led 2 · 2017–26 Spain

Centro para el Desarrollo Tecnológico y la Innovación

www.cdti.es

2 rounds · 2020–26 Spain

EIC Fund

eic.ec.europa.eu

Series A 2026 Luxembourg

Institut Català de Finances

icf.cat

Series A 2026 Spain

AurorA Science

aurorascience.eu ↗

3 rounds, led 2 · 2020–26 Italy

Healthequity SCR

www.healthequity.es ↗

4 rounds, led 1 · 2016–22 Spain

Riva y García

www.rivaygarcia.es ↗

Led Seed 2016 Spain

Business Angels

4 rounds · 2016–22 Spain Private investor

Laudecum

Series A 2026 HQ unknown

Funding rounds 5

·4 not counted

Date	Round	Amount	Lead
2026-03-24	Series A (estimated)	€5.7M	Alta Life Sciences, AurorA Science +4 more
2022-01-18	Series A (estimated)	€5.7M	Lead not disclosed +4 more
2020-12-16	Series A (estimated)	€11.4M	AurorA Science +4 more
2017-09-06	Series A	€4.2M	Alta Life Sciences +2 more
2016-04-28	Seed	€1M	Healthequity, Riva y García +1 more

Not counted (4)

Not counted in totals

2023-10-31	Grant	€2.5M	Lead not disclosed +1 more
2022-01-20	Public Loan	€2.9M	CDTI
2020-01	Public Loan	€1.29M	Lead not disclosed +1 more
2016-01	Public Loan	€850K	Lead not disclosed +1 more

News 1

Open as list →

Published	Article
2026-09-29	Peptomyc cierra una ronda de financiación de 5,7 millones de euros con la entrada del ICF en su accionariado ↗ Capital-Riesgo.es 2026-09-29